BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 38600471)

  • 1. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E.
    Chen EX; Kavan P; Tehfe M; Kortmansky JS; Sawyer MB; Chiorean EG; Lieu CH; Polite B; Wong L; Fakih M; Spencer K; Chaves J; Li C; Leconte P; Adelberg D; Kim R
    Clin Colorectal Cancer; 2024 Jun; 23(2):183-193. PubMed ID: 38653648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
    Bendell JC; Javle M; Bekaii-Saab TS; Finn RS; Wainberg ZA; Laheru DA; Weekes CD; Tan BR; Khan GN; Zalupski MM; Infante JR; Jones S; Papadopoulos KP; Tolcher AW; Chavira RE; Christy-Bittel JL; Barrett E; Patnaik A
    Br J Cancer; 2017 Feb; 116(5):575-583. PubMed ID: 28152546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab With or Without Ipilimumab Combined with Stereotactic Body Radiotherapy in patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study.
    Markussen A; Johansen JS; Larsen FO; Theile S; Hasselby JP; Willemoe GL; Lorentzen T; Madsen K; Høgdall E; Poulsen TS; Wilken EE; Geertsen P; Behrens CP; Svane IM; Nielsen D; Chen IM
    Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38874506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
    Yamamoto N; Kuboki Y; Harano K; Koyama T; Kondo S; Hagiwara A; Suzuki N; Fujikawa E; Toyoizumi K; Mukai M; Doi T
    Invest New Drugs; 2024 Jun; ():. PubMed ID: 38833067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Lentz RW; Friedrich TJ; Blatchford PJ; Jordan KR; Pitts TM; Robinson HR; Davis SL; Kim SS; Leal AD; Lee MR; Waring MRN; Martin AC; Dominguez ATA; Bagby SM; Hartman SJ; Eckhardt SG; Messersmith WA; Lieu CH
    Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38869830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report.
    Shahab SW; Patil P; Fangusaro JR; Patteson B; Goldman-Yassen A; Eaton BR; Boydston W; Schniederjan M; Aguilera D
    Curr Oncol; 2024 Jan; 31(1):579-587. PubMed ID: 38275834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
    Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
    Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated
    Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbè C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzales Cao M; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Curvietto M; Melero I; Palmieri G; Grimaldi AM; Giannarelli D; Dummer R; Chiarion Sileni V
    J Clin Oncol; 2023 Jan; 41(2):212-221. PubMed ID: 36049147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
    Morano F; Raimondi A; Pagani F; Lonardi S; Salvatore L; Cremolini C; Murgioni S; Randon G; Palermo F; Antonuzzo L; Pella N; Racca P; Prisciandaro M; Niger M; Corti F; Bergamo F; Zaniboni A; Ratti M; Palazzo M; Cagnazzo C; Calegari MA; Marmorino F; Capone I; Conca E; Busico A; Brich S; Tamborini E; Perrone F; Di Maio M; Milione M; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2022 May; 40(14):1562-1573. PubMed ID: 35258987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the first-line treatment for metastatic colorectal cancer.
    Cherri S; Oneda E; Zanotti L; Zaniboni A
    Front Oncol; 2023; 13():1246716. PubMed ID: 37909027
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.